April 18, 2024

Influenza Vaccine Market Size To Rake USD 15.66 Bn By 2032

The influenza vaccine market size is poised to grow by USD 15.66 billion by 2032 from USD 7.77 billion in 2023, exhibiting a CAGR of 8.10% during the forecast period 2023-2032.

Influenza Vaccine Market Size 2023 To 2032

Key Takeaways

  • North America contributed more than 47% of the market share in 2022.
  • Asia-Pacific is estimated to witness the fastest CAGR between 2023 and 2032.
  • By vaccine type, the quadrivalent segment has held the largest market share of 65% in 2022.
  • By vaccine type, the trivalent segment is anticipated to grow at a remarkable CAGR of 10.1% between 2023 and 2032.
  • By technology, the egg-based segment generated over 69% of the market share in 2022.
  • By technology, the cell culture segment is expected to expand at the fastest CAGR over the projected period.
  • By age group, the pediatric segment held the largest market share of 59% in 2022.
  • By age group, the adult segment is expected to expand at the fastest CAGR over the projected period.
  • By route of administration, the nasal spray segment generated over 53% of the market share in 2022.
  • By route of administration, the injection segment is expected to expand at the fastest CAGR over the projected period.

Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Influenza vaccine market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.

To begin with, the Influenza vaccine Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.

Get a Sample Report: https://www.precedenceresearch.com/sample/3637

Influenza Vaccine Market Scope

Report Coverage Details
Growth Rate from 2023 to 2032 CAGR of 8.10%
Market Size in 2023 USD 7.77 Billion
Market Size by 2032 USD 15.66 Billion
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Vaccine Type, By Technology, By Age Group, and By Route of Administration
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Medical Alert Systems Market Poised to Exceed $20.92 Bn By 2032

The empirical study on the global Influenza vaccine market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Influenza vaccine Market. Our market report for the Influenza vaccine market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.

Influenza Vaccine Market Players

  • Sanofi Pasteur
  • GlaxoSmithKline plc (GSK)
  • Seqirus (a CSL Limited Company)
  • Pfizer Inc.
  • AstraZeneca
  • BiondVax Pharmaceuticals Ltd.
  • Novavax, Inc.
  • Bharat Biotech
  • Johnson & Johnson
  • MedImmune, LLC (AstraZeneca)
  • FluGen
  • Mitsubishi Tanabe Pharma Corporation
  • Emergent BioSolutions
  • Sinovac Biotech Ltd.
  • Bio Farma

Data Sources and Methodology

To gather comprehensive insights on the Global Influenza vaccine Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.

We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Influenza vaccine Market.

The most resonating, simple, genuine, and important causes because of which you must decide to buy the Influenza vaccine market report exclusively from precedence research

  • The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.

Key Features of the Report:

  • Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
  • Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
  • Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.

Market Segmentation:

By Vaccine Type

  • Quadrivalent
  • Trivalent

By Technology

  • Egg-based
  • Cell culture

By Age Group

  • Pediatric
  • Adult

By Route of Administration

  • Injection
  • Nasal Spray

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Reasons to Consider Purchasing the Report:

  • Enhance your market research capabilities by accessing this comprehensive and precise report on the global Influenza vaccine market.
  • Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
  • Benefit from in-depth research and analysis of the latest trends shaping the global Influenza vaccine market.
  • Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Influenza vaccine market.
  • Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
  • Discover not only the cutting-edge technological advancements in the global Influenza vaccine market but also the strategic plans of industry leaders.

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Influenza Vaccine Market 

5.1. COVID-19 Landscape: Influenza Vaccine Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Influenza Vaccine Market, By Vaccine Type

8.1. Influenza Vaccine Market Revenue and Volume Forecast, by Vaccine Type, 2023-2032

8.1.1. Quadrivalent

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Trivalent

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Influenza Vaccine Market, By Technology

9.1. Influenza Vaccine Market Revenue and Volume Forecast, by Technology, 2023-2032

9.1.1. Egg-based

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Cell culture

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Influenza Vaccine Market, By Age Group 

10.1. Influenza Vaccine Market Revenue and Volume Forecast, by Age Group, 2023-2032

10.1.1. Pediatric

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Adult

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Influenza Vaccine Market, By Route of Administration 

11.1. Influenza Vaccine Market Revenue and Volume Forecast, by Route of Administration, 2023-2032

11.1.1. Injection

11.1.1.1. Market Revenue and Volume Forecast (2020-2032)

11.1.2. Nasal Spray

11.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 12. Global Influenza Vaccine Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.1.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.1.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.1.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.1.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.1.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.1.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.1.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.1.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.1.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.2.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.2.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.2.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.3.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.3.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.3.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.4.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.4.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.4.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.5.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.5.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.5.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)

12.5.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)

12.5.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)

12.5.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

Chapter 13. Company Profiles

13.1. Sanofi Pasteur

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. GlaxoSmithKline plc (GSK)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Seqirus (a CSL Limited Company)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Pfizer Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. AstraZeneca

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. BiondVax Pharmaceuticals Ltd.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Novavax, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Bharat Biotech

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Johnson & Johnson

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. MedImmune, LLC (AstraZeneca)

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

 

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

Precedence Statistics – Empowering Your Data Insights

 

Contact Us

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *